Company news

Pulmatrix, Inc. news in 2022

Pulmatrix, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

November 9, 2022

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

September 25, 2022

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 7, 2022

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

July 11, 2022

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 11, 2022

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

March 28, 2022

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

March 20, 2022

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

March 16, 2022

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

February 28, 2022

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

February 23, 2022

Pulmatrix Issues Letter to Stockholders

January 31, 2022

Decks in 2022